This website is for UK healthcare professionals only and contains promotional content.

Report an adverse event here
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Welcome to the Grünenthal Meds Healthcare Professional Information Hub.

This site contains information on signs, symptoms and management of medical conditions, and is intended for UK Healthcare Professionals only. Login or register to access additional content, including upcoming events and webinars.

If you are a member of the public, patient or caregiver, please click here.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664 000, email: PVUK@grunenthalmeds.com

Therapy Areas

About Us

Grünenthal Meds was established in August 2023, as part of a Joint Venture Collaboration between Grünenthal GmbH and Kyowa Kirin. Headquartered in the UK, we are responsible for managing a portfolio of 13 medicines across six key therapeutic areas, including cancer pain, constipation, and bone health. Through a network of affiliates and key partners, we are bringing these important products to patients in need around the globe. For more information on the Joint Venture Collaboration, please contact infoUK@grunenthalmeds.com

Grünenthal Meds supports the responsible use of opioids. For advice on the responsible use of opioids to treat pain, please click here.

Average:

This website is for healthcare professionals only.

If you are a registered healthcare professional outside the UK please visit the Grünenthal Meds Website

M-GRM-HQ-11-24-0006 May 2025